secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009784
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences reports preliminary $602M cash; outlines 2026 pipeline milestones
--------------------------------------------------------------------------------

- Preliminary unaudited cash $602M as of Dec 31, 2025; runway into 3Q 2028.
- WVE-007 Phase 2a multidose for obesity to start 1H 2026; 400mg 3-mo & 240mg 6-mo data due Q1 2026.
- WVE-006 400mg multidose data from RestorAATion-2 expected Q1 2026; CTA for WVE-008 in 2026.
- NDA filing for WVE-N531 (DMD exon 53 skipping) on track for 2026.
- Plan to submit IND for WVE-003 (Huntington's) with prospective strategic partner.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312526009784/0001193125-26-009784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312526009784/d45710d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer